Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Two-Day Regimen of Dihydroartemisinin-Piperaquine for Malaria Prevention Halted for Concern over Prolonged Corrected QT Interval

Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Manning, Jessica, Vanachayangkul, Pattaraporn, Lon, Chanthap, Spring, Michele, So, Mary, Sea, Darapiseth, Se, Youry, Somethy, Sok, Phann, Sut-Thang, Chann, Soklyda, Sriwichai, Sabaithip, Buathong, Nillawan, Kuntawunginn, Worachet, Mitprasat, Mashamon, Siripokasupkul, Raveewan, Teja-Isavadharm, Paktiya, Soh, Eugene, Timmermans, Ans, Lanteri, Charlotte, Kaewkungwal, Jaranit, Auayporn, Montida, Tang, Douglas, Chour, Char Meng, Prom, Satharath, Haigney, Mark, Cantilena, Louis, Saunders, David
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4187937/
https://ncbi.nlm.nih.gov/pubmed/25092702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02667-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados